Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 5/20 | 0.31 |
| ▸ | CTSK | P43235 | 4/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31479851 | 0.93 | MEN1 (0.42) | MEN1KMT2AKCNH2CTSCCTSK | |
| SCHEMBL31479550 | 0.86 | MEN1 (0.40) | MEN1KMT2ACTSCCTSK | |
| SCHEMBL31479709 | 0.85 | MEN1 (0.43) | MEN1KMT2AKCNH2HCRTR1HCRTR2 | |
| SCHEMBL31479716 | 0.85 | MEN1 (0.38) | MEN1KMT2ACTSCCTSK | |
| SCHEMBL31479890 | 0.82 | HCRTR1 (0.36) | MEN1KMT2AKCNH2HCRTR1HCRTR2 | |
| SCHEMBL31479928 | 0.81 | ALOX5AP (0.35) | MEN1KMT2AKCNH2HCRTR1HCRTR2 | |
| SCHEMBL31479531 | 0.81 | PREP (0.37) | MEN1KMT2AKCNH2 | |
| SCHEMBL31479415 | 0.79 | MEN1 (0.41) | MEN1KMT2AKCNH2HCRTR1HCRTR2 | |
| SCHEMBL31479949 | 0.77 | MEN1 (0.53) | MEN1KMT2AKCNH2HCRTR1HCRTR2 | |
| SCHEMBL31479353 | 0.74 | ALOX5AP (0.35) | MEN1KMT2AKCNH2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |